Rhinomed Ltd
ASX:RNO
Rhinomed Ltd
Net Income (Common)
Rhinomed Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rhinomed Ltd
ASX:RNO
|
Net Income (Common)
-AU$10.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
6%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Income (Common)
AU$117.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Income (Common)
AU$157.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Income (Common)
-AU$14.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-24%
|
|
Probiotec Ltd
ASX:PBP
|
Net Income (Common)
AU$8.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
21%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Net Income (Common)
-AU$24.6m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rhinomed Ltd's Net Income (Common)?
Net Income (Common)
-10.9m
AUD
Based on the financial report for Jun 30, 2023, Rhinomed Ltd's Net Income (Common) amounts to -10.9m AUD.
What is Rhinomed Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
6%
Over the last year, the Net Income (Common) growth was -107%. The average annual Net Income (Common) growth rates for Rhinomed Ltd have been -15% over the past three years , -22% over the past five years , and 6% over the past ten years .